ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,196, issued on Feb. 3, was assigned to Kite Pharma Inc. (Santa Monica, Calif.).
"GPC3 binding molecules" was invented by Matthew Drever (Concord, Calif.), Gabrielle M. Romain (Albany, Calif.), Sarah K. Wyman (Washington) and Chi Ying (Oakland, Calif.).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the GPC3 binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment."
The patent was filed on June 7, 2022, under Application No. 17/834,...